An exploratory study of psychosis risk factors in individuals who are referred but do not meet criteria for an early intervention in psychosis service.

BJPsych Open

Dublin and East Treatment and Early Care Team (DETECT) Early Intervention in Psychosis Service, Dublin, Ireland; and School of Medicine, University College Dublin, Ireland.

Published: January 2024

Background: The 'at-risk mental state' (ARMS) for psychosis has been critiqued for its limited prognostic ability and identification of a limited proportion of those who will develop a first episode of psychosis (FEP). Broadening the search for high-risk groups is key to improving population-level ascertainment of psychosis risk.

Aims: To explore risk enrichment in diagnostic, demographic and socio-functional domains among individuals referred to an early intervention in psychosis (EIP) service not meeting ARMS or FEP criteria.

Method: A retrospective file review of 16 years of referrals to a tertiary EIP service in Ireland was undertaken. Diagnostic outcomes from standardised assessments (Structured Clinical Interview for DSM), demographic (age, gender, family history, nationality) and socio-occupational (relationship status, living status, working status) variables were compiled for those not meeting criteria. These were compared with individuals diagnosed with an FEP in the same period.

Results: From 2005 to 2021 inclusive, of 2025 index assessments, 27.6% ( = 558) did not meet either FEP or ARMS criteria, which is notably higher than the 5.4% ( = 110) meeting ARMS criteria. This group had high psychiatric morbidity, with 65.4% meeting criteria for at least one DSM Axis I disorder. Depressive, anxiety and substance use disorders predominated. Their functional markers were poor, and comparable to the FEP cohort.

Conclusions: This group is enriched for psychosis risk factors. They are a larger group than those meeting ARMS criteria, a finding that may reflect EIP service configuration. They may be an important focus for further study in the search for at-risk populations beyond the current ARMS model.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10790220PMC
http://dx.doi.org/10.1192/bjo.2023.640DOI Listing

Publication Analysis

Top Keywords

eip service
12
meeting arms
12
arms criteria
12
psychosis risk
8
risk factors
8
individuals referred
8
early intervention
8
intervention psychosis
8
meeting criteria
8
psychosis
7

Similar Publications

There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions and decisions for study sponsors, from preclinical research through clinical trial design to regulatory, statistical, and operational considerations. In January 2024, the Alzheimer's Drug Discovery Foundation convened an expert advisory board to discuss the key considerations in each of these areas.

View Article and Find Full Text PDF

Background: Disease-modifying therapies targeting the diverse pathophysiology of Alzheimer's disease (AD), including neuroinflammation, represent potentially important and novel approaches. The glucagon-like peptide-1 receptor agonist semaglutide is approved for the treatment of type 2 diabetes and obesity and has an established safety profile. Semaglutide may have a disease-modifying, neuroprotective effect in AD through multimodal mechanisms including neuroinflammatory, vascular, and other AD-related processes.

View Article and Find Full Text PDF

Learning Health Systems (LHSs) strive to continuously integrate innovations and evidence-based practices in healthcare settings, thereby enhancing programmatic and patient outcomes. Duration of untreated psychosis (DUP) is a variable worthy of empirical attention, as the construct has been identified as a leading predictor of psychotic spectrum disorder prognosis and, despite the proliferation of early intervention for psychosis (EIP) teams across the U.S.

View Article and Find Full Text PDF
Article Synopsis
  • The study highlights the growing need for accurate estimates of the Alzheimer's disease (AD) and mild cognitive impairment (MCI) population in the healthcare system due to new anti-amyloid therapies.
  • It utilizes Medicare beneficiary data to analyze trends in the incidence and prevalence of AD and MCI between 2008-2018, finding that while AD incidence declined, MCI incidence significantly increased but maintained a stable overall prevalence.
  • The results reveal that among Medicare beneficiaries, AD prevalence rose, particularly for MCI, and identified older age, female sex, and residing in the Northeastern U.S. as factors associated with higher prevalence rates.
View Article and Find Full Text PDF

Objectives: To assess the impact of the COVID-19 pandemic on first-episode psychosis (FEP) presentations across two Early Intervention in Psychosis (EIP) services in Ireland, by comparing pre-pandemic and post-pandemic cohorts.

Methods: A cross-sectional observational design with retrospective medical record review was employed. The study population comprised 187 FEP patients (77 in pre-pandemic and 110 in post-pandemic cohort).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!